Vaccines: Accelerating Innovation and Access

Vaccines: Accelerating Innovation and Access PDF Author: World Intellectual Property Organization
Publisher: WIPO
ISBN:
Category : Law
Languages : en
Pages : 32

Get Book Here

Book Description
This Global Challenges Report describes the innovation process for vaccines. It explains how the restricted availability of vaccines is due to impediments at every stage of the process. Most of these obstacles are manageable, and intellectual property (IP) rights are associated with only some of them. The analysis aims to put into perspective debates around health innovation and the availability of health technologies in developing countries, especially with respect to the role of IP. In particular, it provides an overview of how IP has been used to meet global health challenges in the vaccines field, and considers whether lessons can be drawn to inform other important health technologies.

Vaccines: Accelerating Innovation and Access

Vaccines: Accelerating Innovation and Access PDF Author: World Intellectual Property Organization
Publisher: WIPO
ISBN:
Category : Law
Languages : en
Pages : 32

Get Book Here

Book Description
This Global Challenges Report describes the innovation process for vaccines. It explains how the restricted availability of vaccines is due to impediments at every stage of the process. Most of these obstacles are manageable, and intellectual property (IP) rights are associated with only some of them. The analysis aims to put into perspective debates around health innovation and the availability of health technologies in developing countries, especially with respect to the role of IP. In particular, it provides an overview of how IP has been used to meet global health challenges in the vaccines field, and considers whether lessons can be drawn to inform other important health technologies.

Promoting Access to Medical Technologies and Innovation - Intersections between Public Health, Intellectual Property and Trade

Promoting Access to Medical Technologies and Innovation - Intersections between Public Health, Intellectual Property and Trade PDF Author: World Intellectual Property Organization
Publisher: WIPO
ISBN: 9280523082
Category : Law
Languages : en
Pages : 259

Get Book Here

Book Description
This study has emerged from an ongoing program of trilateral cooperation between WHO, WTO and WIPO. It responds to an increasing demand, particularly in developing countries, for strengthened capacity for informed policy-making in areas of intersection between health, trade and IP, focusing on access to and innovation of medicines and other medical technologies.

Innovative Technology in the Water, Sanitation and Hygiene (WASH) Sector

Innovative Technology in the Water, Sanitation and Hygiene (WASH) Sector PDF Author: Oksen, Peter
Publisher: WIPO
ISBN:
Category : Law
Languages : en
Pages : 12

Get Book Here

Book Description
Access to adequate water, sanitation and hygiene (WASH) embodies a fun- damental human right recognized by the United Nations General Assembly. Technology often plays an important role by providing resource-efficient solutions to some of the challenges associated with WASH. This edition of the Global Challenges in Focus series explores the water supply aspect of WASH and highlights the role of technological innovation in relation to managing limited freshwater resources in situations of scarcity and/or threats to the quality of the water supply.

Blue Marble Health

Blue Marble Health PDF Author: Peter J. Hotez
Publisher: JHU Press
ISBN: 1421420465
Category : Law
Languages : en
Pages : 224

Get Book Here

Book Description
Why do diseases of poverty afflict more people in wealthy countries than in the developing world? In 2011, Dr. Peter J. Hotez relocated to Houston to launch Baylor’s National School of Tropical Medicine. He was shocked to discover that a number of neglected diseases often associated with developing countries were widespread in impoverished Texas communities. Despite the United States’ economic prowess and first-world status, an estimated 12 million Americans living at the poverty level currently suffer from at least one neglected tropical disease, or NTD. Hotez concluded that the world’s neglected diseases—which include tuberculosis, hookworm infection, lymphatic filariasis, Chagas disease, and leishmaniasis—are born first and foremost of extreme poverty. In this book, Hotez describes a new global paradigm known as “blue marble health,” through which he asserts that poor people living in wealthy countries account for most of the world’s poverty-related illness. He explores the current state of neglected diseases in such disparate countries as Mexico, South Korea, Argentina, Australia, the United States, Japan, and Nigeria. By crafting public policy and relying on global partnerships to control or eliminate some of the world’s worst poverty-related illnesses, Hotez believes, it is possible to eliminate life-threatening disease while at the same time creating unprecedented opportunities for science and diplomacy. Clear, compassionate, and timely, Blue Marble Health is a must-read for leaders in global health, tropical medicine, and international development, along with anyone committed to helping the millions of people who are caught in the desperate cycle of poverty and disease.

Making Markets for Vaccines

Making Markets for Vaccines PDF Author: Owen Barder
Publisher:
ISBN:
Category : Business & Economics
Languages : en
Pages : 132

Get Book Here

Book Description
A legacy of our generation -- Ch. 1. We need to invest more in vaccines -- Ch. 2. Promoting private investment in vaccine development -- Ch. 3. A market not a prize -- Ch. 4. Design choices -- Ch. 5. $3 billion per disease -- Ch. 6. Meeting industry requirements -- Ch. 7. How sponsors can do it.

WHO Expert Committee on Specifications for Pharmaceutical Preparations

WHO Expert Committee on Specifications for Pharmaceutical Preparations PDF Author:
Publisher: World Health Organization
ISBN: 924002090X
Category : Medical
Languages : en
Pages : 324

Get Book Here

Book Description
The Expert Committee on Specifications for Pharmaceutical Preparations works towards clear, independent and practical standards and guidelines for the quality assurance of medicines and provision of global regulatory tools. Standards are developed by the Expert Committee through worldwide consultation and an international consensus-building process. The following new guidance texts were adopted and recommended for use: Guidelines and guidance texts adopted by the Expert Committee on Specifications for Pharmaceutical Preparations; Points to consider when including Health Based Exposure Limits (HBELs) in cleaning validation; Good manufacturing practices: water for pharmaceutical use; Guideline on data integrity; WHO/United Nations Population Fund recommendations for condom storage and shipping temperatures; WHO/United Nations Population Fund guidance on testing of male latex condoms; WHO/United Nations Population Fund guidance on conducting post-market surveillance of condoms; WHO “Biowaiver List”: proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms; WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce; Good reliance practices in the regulation of medical products: high-level principles and considerations; and Good regulatory practices in the regulations of medical products. All of the above are included in this report and recommended for implementation.

Definition and Application of Terms for Vaccine Pharmacovigilance

Definition and Application of Terms for Vaccine Pharmacovigilance PDF Author: Council for International Organizations of Medical Sciences (CIOMS)
Publisher:
ISBN: 9789290360834
Category : Drug Monitoring
Languages : en
Pages : 0

Get Book Here

Book Description
This report from the Council for International Organizations of Medical Sciences (CIOMS) in collaboration with WHO covers the activities and outputs of the CIOMS/WHO Working Group on Vaccine Pharmacovigilance (2005-2010). This working group brought together experts from both industrialized and emerging countries representing regulatory agencies, vaccine industry, national and international public health bodies including WHO and CIOMS, academia and clinical care, contributing from their different perspectives. The report covers general terms and definitions for vaccine safety and discusses the application of such harmonized tools in vaccine safety surveillance and studies. As well, the report highlights case definitions for adverse events typically reported for vaccines. The report is addressed to those engaged in vaccine safety data collection and evaluation, and will also make a useful reading for others who want to familiarize themselves with vaccine safety terminology.

Priorities for the National Vaccine Plan

Priorities for the National Vaccine Plan PDF Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309156203
Category : Medical
Languages : en
Pages : 368

Get Book Here

Book Description
Vaccination is a fundamental component of preventive medicine and public health. The use of vaccines to prevent infectious diseases has resulted in dramatic decreases in disease, disability, and death in the United States and around the world. The current political, economic, and social environment presents both opportunities for and challenges to strengthening the U.S. system for developing, manufacturing, regulating, distributing, funding, and administering safe and effective vaccines for all people. Priorities for the National Vaccine Plan examines the extraordinarily complex vaccine enterprise, from research and development of new vaccines to financing and reimbursement of immunization services. Priorities for the National Vaccine Plan examines the extraordinarily complex vaccine enterprise, from research and development of new vaccines to financing and reimbursement of immunization services. The book makes recommendations about priority actions in the update to the National Vaccine Plan that are intended to achieve the objectives of disease prevention and enhancement of vaccine safety. It is centered on the plan's five goals in the areas of vaccine development, safety, communication, supply and use, and global health.

Small Molecules and Peptide-Based Candidates as Therapeutics and Vaccines for COVID-19 Pandemic

Small Molecules and Peptide-Based Candidates as Therapeutics and Vaccines for COVID-19 Pandemic PDF Author: Da’san Mahmoud Mousa Jaradat
Publisher: Frontiers Media SA
ISBN: 2889716473
Category : Science
Languages : en
Pages : 419

Get Book Here

Book Description
Topic Editor Dr. Balakumar Chandrasekaran holds patents relating to N-substituted isatin hydrazones as antimycobacterial and antimicrobial agents, and Pharmaceutical Compounds. Topic Editor Dr. Munir Al-Zeer holds a patent relating to Method for the Preparation of an Influenza Virus. All other Topic Editors declare no competing interests.

SBIR and the Phase III Challenge of Commercialization

SBIR and the Phase III Challenge of Commercialization PDF Author: National Research Council
Publisher: National Academies Press
ISBN: 0309179106
Category : Political Science
Languages : en
Pages : 200

Get Book Here

Book Description
In response to a Congressional mandate, the National Research Council conducted a review of the Small Business Innovation Research Program (SBIR) at the five federal agencies with SBIR programs with budgets in excess of $100 million (DOD, NIH, NASA, DOE, and NSF). The project was designed to answer questions of program operation and effectiveness, including the quality of the research projects being conducted under the SBIR program, the commercialization of the research, and the program's contribution to accomplishing agency missions. This report summarizes the presentations at a symposium exploring the effectiveness of Phase III of the SBIR program (the commercialization phase), during which innovations funded by Phase II awards move from the laboratory into the marketplace. No SBIR funds support Phase III; instead, to commercialize their products, small businesses are expected to garner additional funds from private investors, the capital markets, or from the agency that made the initial award.